{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T20:39:36Z","timestamp":1776458376960,"version":"3.51.2"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Internal grant."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41434-025-00518-9","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:03:07Z","timestamp":1739952187000},"page":"410-420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["AAV1.NT3 gene therapy mitigates the severity of autoimmune encephalomyelitis in the mouse model for multiple sclerosis"],"prefix":"10.1038","volume":"32","author":[{"given":"Lingying","family":"Tong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5739-5419","authenticated-orcid":false,"given":"Burcak","family":"Ozes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Moss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zayed","family":"Attia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana A.","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Trapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2974-3943","authenticated-orcid":false,"given":"Zarife","family":"Sahenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"518_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-pathol-052920-040318","volume":"17","author":"S Rodriguez Murua","year":"2022","unstructured":"Rodriguez Murua S, Farez MF, Quintana FJ. The immune response in multiple sclerosis. Annu Rev Pathol. 2022;17:121\u201339.","journal-title":"Annu Rev Pathol"},{"key":"518_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri3871","volume":"15","author":"CA Dendrou","year":"2015","unstructured":"Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15:545\u201358.","journal-title":"Nat Rev Immunol"},{"key":"518_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1056\/NEJM199801293380502","volume":"338","author":"BD Trapp","year":"1998","unstructured":"Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278\u201385.","journal-title":"N Engl J Med"},{"key":"518_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/jnen\/61.1.23","volume":"61","author":"JR Wujek","year":"2002","unstructured":"Wujek JR, Bjartmar C, Richer E, Ransohoff RM, Yu M, Tuohy VK, et al. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol. 2002;61:23\u201332.","journal-title":"J Neuropathol Exp Neurol"},{"key":"518_CR5","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1212\/01.wnl.0000275229.13012.32","volume":"68","author":"R Dutta","year":"2007","unstructured":"Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology. 2007;68:S22\u201331. discussion S43-54","journal-title":"Neurology"},{"key":"518_CR6","doi-asserted-by":"publisher","first-page":"e1810","DOI":"10.1212\/WNL.0000000000200150","volume":"98","author":"B Bebo","year":"2022","unstructured":"Bebo B, Cintina I, LaRocca N, Ritter L, Talente B, Hartung D, et al. The economic burden of multiple sclerosis in the United States: estimate of direct and indirect costs. Neurology. 2022;98:e1810\u2013e1817.","journal-title":"Neurology"},{"key":"518_CR7","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1089\/jir.2014.0025","volume":"34","author":"BM Segal","year":"2014","unstructured":"Segal BM. Stage-specific immune dysregulation in multiple sclerosis. J Interferon Cytokine Res. 2014;34:633\u201340.","journal-title":"J Interferon Cytokine Res"},{"key":"518_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01571-8","volume":"8","author":"D Hu","year":"2017","unstructured":"Hu D, Notarbartolo S, Croonenborghs T, Patel B, Cialic R, Yang TH, et al. Transcriptional signature of human pro-inflammatory T(H)17 cells identifies reduced IL10 gene expression in multiple sclerosis. Nat Commun. 2017;8:1600.","journal-title":"Nat Commun"},{"key":"518_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","volume":"14","author":"DH Mahad","year":"2015","unstructured":"Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14:183\u201393.","journal-title":"Lancet Neurol"},{"key":"518_CR10","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133:1380\u201390 e1382.","journal-title":"Am J Med"},{"key":"518_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2018.03.003","volume":"189","author":"BM Segal","year":"2018","unstructured":"Segal BM. Modulation of the innate immune system: a future approach to the treatment of neurological disease. Clin Immunol. 2018;189:1\u20133.","journal-title":"Clin Immunol"},{"key":"518_CR12","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/neu.480251107","volume":"25","author":"M Barbacid","year":"1994","unstructured":"Barbacid M. The Trk family of neurotrophin receptors. J Neurobiol. 1994;25:1386\u2013403.","journal-title":"J Neurobiol"},{"key":"518_CR13","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1242\/dev.126.10.2191","volume":"126","author":"EJ Huang","year":"1999","unstructured":"Huang EJ, Wilkinson GA, Farinas I, Backus C, Zang K, Wong SL, et al. Expression of Trk receptors in the developing mouse trigeminal ganglion: in vivo evidence for NT-3 activation of TrkA and TrkB in addition to TrkC. Development. 1999;126:2191\u2013203.","journal-title":"Development"},{"key":"518_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1750-3639.2006.00038.x","volume":"16","author":"Z Sahenk","year":"2006","unstructured":"Sahenk Z. Neurotrophins and peripheral neuropathies. Brain Pathol. 2006;16:311\u20139.","journal-title":"Brain Pathol"},{"key":"518_CR15","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s12035-014-8706-9","volume":"50","author":"M Richner","year":"2014","unstructured":"Richner M, Ulrichsen M, Elmegaard SL, Dieu R, Pallesen LT, Vaegter CB. Peripheral nerve injury modulates neurotrophin signaling in the peripheral and central nervous system. Mol Neurobiol. 2014;50:945\u201370.","journal-title":"Mol Neurobiol"},{"key":"518_CR16","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1523\/JNEUROSCI.19-10-03847.1999","volume":"19","author":"C Meier","year":"1999","unstructured":"Meier C, Parmantier E, Brennan A, Mirsky R, Jessen KR. Developing Schwann cells acquire the ability to survive without axons by establishing an autocrine circuit involving insulin-like growth factor, neurotrophin-3, and platelet-derived growth factor-BB. J Neurosci. 1999;19:3847\u201359.","journal-title":"J Neurosci"},{"key":"518_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0165-2478(03)00080-4","volume":"88","author":"M Sekimoto","year":"2003","unstructured":"Sekimoto M, Tsuji T, Matsuzaki J, Chamoto K, Koda T, Nemoto K, et al. Functional expression of the TrkC gene, encoding a high affinity receptor for NT-3, in antigen-specific T helper type 2 (Th2) cells. Immunol Lett. 2003;88:221\u20136.","journal-title":"Immunol Lett"},{"key":"518_CR18","doi-asserted-by":"crossref","unstructured":"Yalvac ME, Arnold WD, Braganza C, Chen L, Mendell JR, Sahenk Z. AAV1.NT-3 gene therapy attenuates spontaneous autoimmune peripheral polyneuropathy. Gene Therapy 2015;23:95\u2013102.","DOI":"10.1038\/gt.2015.67"},{"key":"518_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/mt.2013.250","volume":"22","author":"Z Sahenk","year":"2014","unstructured":"Sahenk Z, Galloway G, Clark KR, Malik V, Rodino-Klapac LR, Kaspar BK, et al. AAV1.NT-3 gene therapy for Charcot-marie-tooth neuropathy. Mol Ther. 2014;22:511\u201321.","journal-title":"Mol Ther"},{"key":"518_CR20","doi-asserted-by":"crossref","unstructured":"Yalvac ME, Amornvit J, Chen L, Shontz KM, Lewis S, Sahenk Z. AAV1.NT-3 gene therapy increases muscle fiber diameter through activation of mTOR pathway and metabolic remodeling in a CMT mouse model. Gene Therapy 2018;25:129\u201338.","DOI":"10.1038\/s41434-018-0009-8"},{"key":"518_CR21","doi-asserted-by":"crossref","unstructured":"Ozes B, Myers M, Moss K, McKinney J, Ridgley A, Chen L, et al. AAV1.NT-3 gene therapy for X-linked Charcot-Marie-Tooth neuropathy type 1. Gene Therapy 2021;29:127\u201337.","DOI":"10.1038\/s41434-021-00231-3"},{"key":"518_CR22","doi-asserted-by":"publisher","first-page":"fcab252","DOI":"10.1093\/braincomms\/fcab252","volume":"3","author":"B Ozes","year":"2021","unstructured":"Ozes B, Moss K, Myers M, Ridgley A, Chen L, Murrey D, et al. AAV1.NT-3 gene therapy in a CMT2D model: phenotypic improvements in Gars(P278KY\/+) mice. Brain Commun. 2021;3:fcab252.","journal-title":"Brain Commun"},{"key":"518_CR23","first-page":"1306","volume":"15","author":"B Ozes","year":"2023","unstructured":"Ozes B, Tong L, Myers M, Moss K, Ridgley A, Sahenk Z. AAV1.NT-3 gene therapy prevents age-related sarcopenia. Aging. 2023;15:1306\u201329.","journal-title":"Aging"},{"key":"518_CR24","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1212\/01.WNL.0000171978.70849.c5","volume":"65","author":"Z Sahenk","year":"2005","unstructured":"Sahenk Z, Nagaraja HN, McCracken BS, King WM, Freimer ML, Cedarbaum JM, et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology. 2005;65:681\u20139.","journal-title":"Neurology"},{"key":"518_CR25","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/gt.2012.100","volume":"20","author":"C Beutner","year":"2013","unstructured":"Beutner C, Lepperhof V, Dann A, Linnartz-Gerlach B, Litwak S, Napoli I, et al. Engineered stem cell-derived microglia as therapeutic vehicle for experimental autoimmune encephalomyelitis. Gene Ther. 2013;20:797\u2013806.","journal-title":"Gene Ther"},{"key":"518_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/367371a0","volume":"367","author":"BA Barres","year":"1994","unstructured":"Barres BA, Raff MC, Gaese F, Bartke I, Dechant G, Barde YA. A crucial role for neurotrophin-3 in oligodendrocyte development. Nature. 1994;367:371\u20135.","journal-title":"Nature"},{"key":"518_CR27","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/glia.20888","volume":"57","author":"RP Coelho","year":"2009","unstructured":"Coelho RP, Yuelling LM, Fuss B, Sato-Bigbee C. Neurotrophin-3 targets the translational initiation machinery in oligodendrocytes. Glia. 2009;57:1754\u201364.","journal-title":"Glia"},{"key":"518_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1242\/dev.118.1.283","volume":"118","author":"BA Barres","year":"1993","unstructured":"Barres BA, Schmid R, Sendnter M, Raff MC. Multiple extracellular signals are required for long-term oligodendrocyte survival. Development. 1993;118:283\u201395.","journal-title":"Development"},{"key":"518_CR29","first-page":"15 11 11","volume":"Chapter 15","author":"SD Miller","year":"2007","unstructured":"Miller SD, Karpus WJ. Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol. 2007;Chapter 15:15 11 11\u201315 11 18.","journal-title":"Curr Protoc Immunol"},{"key":"518_CR30","doi-asserted-by":"publisher","first-page":"e00137","DOI":"10.1002\/prp2.137","volume":"3","author":"N Khan","year":"2015","unstructured":"Khan N, Gordon R, Woodruff TM, Smith MT. Antiallodynic effects of alpha lipoic acid in an optimized RR-EAE mouse model of MS-neuropathic pain are accompanied by attenuation of upregulated BDNF-TrkB-ERK signaling in the dorsal horn of the spinal cord. Pharmacol Res Perspect. 2015;3:e00137.","journal-title":"Pharmacol Res Perspect"},{"key":"518_CR31","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/mt.2009.293","volume":"18","author":"MG Toscano","year":"2010","unstructured":"Toscano MG, Delgado M, Kong W, Martin F, Skarica M, Ganea D. Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Mol Ther. 2010;18:1035\u201345.","journal-title":"Mol Ther"},{"key":"518_CR32","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/eji.201747264","volume":"48","author":"Z Attia","year":"2018","unstructured":"Attia Z, Rowe JC, Kim E, Varikuti S, Steiner HE, Zaghawa A, et al. Inhibitors of elastase stimulate murine B lymphocyte differentiation into IgG- and IgA-producing cells. Eur J Immunol. 2018;48:1295\u2013301.","journal-title":"Eur J Immunol"},{"key":"518_CR33","doi-asserted-by":"publisher","first-page":"e2102435118","DOI":"10.1073\/pnas.2102435118","volume":"118","author":"E Kim","year":"2021","unstructured":"Kim E, Attia Z, Woodfint RM, Zeng C, Kim SH, Steiner HE, et al. Inhibition of elastase enhances the adjuvanticity of alum and promotes anti-SARS-CoV-2 systemic and mucosal immunity. Proc Natl Acad Sci USA. 2021;118:e2102435118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"518_CR34","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/mt.2014.77","volume":"22","author":"ME Yalvac","year":"2014","unstructured":"Yalvac ME, Arnold WD, Hussain SR, Braganza C, Shontz KM, Clark KR, et al. VIP-expressing dendritic cells protect against spontaneous autoimmune peripheral polyneuropathy. Mol Ther. 2014;22:1353\u201363.","journal-title":"Mol Ther"},{"key":"518_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/7651_2014_88","volume":"1304","author":"RL Terry","year":"2016","unstructured":"Terry RL, Ifergan I, Miller SD. Experimental autoimmune encephalomyelitis in mice. Methods Mol Biol. 2016;1304:145\u201360.","journal-title":"Methods Mol Biol"},{"key":"518_CR36","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/978-1-4939-7862-5_17","volume":"1791","author":"M Giralt","year":"2018","unstructured":"Giralt M, Molinero A, Hidalgo J. Active induction of experimental autoimmune encephalomyelitis (EAE) with MOG(35-55) in the mouse. Methods Mol Biol. 2018;1791:227\u201332.","journal-title":"Methods Mol Biol"},{"key":"518_CR37","doi-asserted-by":"publisher","first-page":"100477","DOI":"10.1016\/j.bbih.2022.100477","volume":"23","author":"J Faraji","year":"2022","unstructured":"Faraji J, Bettenson D, Babatunde S, Gangur-Powell T, Yong VW, Metz GAS. Thermoregulatory dynamics reveal sex-specific inflammatory responses to experimental autoimmune encephalomyelitis in mice: implications for multiple sclerosis-induced fatigue in females. Brain Behav Immun Health. 2022;23:100477.","journal-title":"Brain Behav Immun Health"},{"key":"518_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0892-8","volume":"14","author":"KM Danikowski","year":"2017","unstructured":"Danikowski KM, Jayaraman S, Prabhakar BS. Regulatory T cells in multiple sclerosis and myasthenia gravis. J Neuroinflammation. 2017;14:117.","journal-title":"J Neuroinflammation"},{"key":"518_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jneuroim.2014.09.016","volume":"277","author":"BD Clarkson","year":"2014","unstructured":"Clarkson BD, Walker A, Harris M, Rayasam A, Sandor M, Fabry Z. Mapping the accumulation of co-infiltrating CNS dendritic cells and encephalitogenic T cells during EAE. J Neuroimmunol. 2014;277:39\u201349.","journal-title":"J Neuroimmunol"},{"key":"518_CR40","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nm1197","volume":"11","author":"M Greter","year":"2005","unstructured":"Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T, et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med. 2005;11:328\u201334.","journal-title":"Nat Med"},{"key":"518_CR41","doi-asserted-by":"publisher","first-page":"175628642110076","DOI":"10.1177\/17562864211007687","volume":"14","author":"S Haase","year":"2021","unstructured":"Haase S, Linker RA. Inflammation in multiple sclerosis. Ther Adv Neurol Disord. 2021;14:17562864211007687.","journal-title":"Ther Adv Neurol Disord"},{"key":"518_CR42","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","volume":"9","author":"H Lassmann","year":"2018","unstructured":"Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2018;9:3116.","journal-title":"Front Immunol"},{"key":"518_CR43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nm.2324","volume":"17","author":"I Nikic","year":"2011","unstructured":"Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med. 2011;17:495\u20139.","journal-title":"Nat Med"},{"key":"518_CR44","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/S1474-4422(18)30245-X","volume":"17","author":"BD Trapp","year":"2018","unstructured":"Trapp BD, Vignos M, Dudman J, Chang A, Fisher E, Staugaitis SM, et al. Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study. Lancet Neurol. 2018;17:870\u201384.","journal-title":"Lancet Neurol"},{"key":"518_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.expneurol.2015.11.010","volume":"277","author":"K Ohl","year":"2016","unstructured":"Ohl K, Tenbrock K, Kipp M. Oxidative stress in multiple sclerosis: central and peripheral mode of action. Exp Neurol. 2016;277:58\u201367.","journal-title":"Exp Neurol"},{"key":"518_CR46","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S1474-4422(15)00381-6","volume":"15","author":"SW Way","year":"2016","unstructured":"Way SW, Popko B. Harnessing the integrated stress response for the treatment of multiple sclerosis. Lancet Neurol. 2016;15:434\u201343.","journal-title":"Lancet Neurol"},{"key":"518_CR47","doi-asserted-by":"publisher","first-page":"e1583","DOI":"10.1002\/wsbm.1583","volume":"15","author":"GM Mey","year":"2023","unstructured":"Mey GM, Mahajan KR, DeSilva TM. Neurodegeneration in multiple sclerosis. WIREs Mech Dis. 2023;15:e1583.","journal-title":"WIREs Mech Dis"},{"key":"518_CR48","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1093\/brain\/119.6.2009","volume":"119","author":"NA Losseff","year":"1996","unstructured":"Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain. 1996;119:2009\u201319.","journal-title":"Brain"},{"key":"518_CR49","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278\u201386.","journal-title":"Neurology"},{"key":"518_CR50","doi-asserted-by":"publisher","first-page":"105697","DOI":"10.1016\/j.neuint.2024.105697","volume":"175","author":"A Haque","year":"2024","unstructured":"Haque A, Trager NNM, Butler JT, Das A, Zaman V, Banik NL. A novel combination approach to effectively reduce inflammation and neurodegeneration in multiple sclerosis models. Neurochem Int. 2024;175:105697.","journal-title":"Neurochem Int"},{"key":"518_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13577-023-01006-1","volume":"37","author":"MV Christodoulou","year":"2024","unstructured":"Christodoulou MV, Petkou E, Atzemoglou N, Gkorla E, Karamitrou A, Simos YV, et al. Cell replacement therapy with stem cells in multiple sclerosis, a systematic review. Hum Cell. 2024;37:9\u201353.","journal-title":"Hum Cell"},{"key":"518_CR52","doi-asserted-by":"publisher","first-page":"11279","DOI":"10.1073\/pnas.92.24.11279","volume":"92","author":"A Karavanov","year":"1995","unstructured":"Karavanov A, Sainio K, Palgi J, Saarma M, Saxen L, Sariola H. Neurotrophin 3 rescues neuronal precursors from apoptosis and promotes neuronal differentiation in the embryonic metanephric kidney. Proc Natl Acad Sci USA. 1995;92:11279\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"key":"518_CR53","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/(SICI)1098-1136(199811)24:3<272::AID-GLIA2>3.0.CO;2-4","volume":"24","author":"K Nakajima","year":"1998","unstructured":"Nakajima K, Kikuchi Y, Ikoma E, Honda S, Ishikawa M, Liu Y, et al. Neurotrophins regulate the function of cultured microglia. Glia. 1998;24:272\u201389.","journal-title":"Glia"},{"key":"518_CR54","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/jcb.10658","volume":"90","author":"SF Tzeng","year":"2003","unstructured":"Tzeng SF, Huang HY. Downregulation of inducible nitric oxide synthetase by neurotrophin-3 in microglia. J Cell Biochem. 2003;90:227\u201333.","journal-title":"J Cell Biochem"},{"key":"518_CR55","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/jnr.20586","volume":"81","author":"SF Tzeng","year":"2005","unstructured":"Tzeng SF, Huang HY, Lee TI, Jwo JK. Inhibition of lipopolysaccharide-induced microglial activation by preexposure to neurotrophin-3. J Neurosci Res. 2005;81:666\u201376.","journal-title":"J Neurosci Res"},{"key":"518_CR56","doi-asserted-by":"publisher","first-page":"e49494","DOI":"10.7554\/eLife.49494","volume":"8","author":"L Armijo-Weingart","year":"2019","unstructured":"Armijo-Weingart L, Ketschek A, Sainath R, Pacheco A, Smith GM, Gallo G. Neurotrophins induce fission of mitochondria along embryonic sensory axons. eLife. 2019;8:e49494.","journal-title":"eLife"},{"key":"518_CR57","doi-asserted-by":"publisher","first-page":"e01118","DOI":"10.1002\/brb3.1118","volume":"8","author":"Z Sahenk","year":"2018","unstructured":"Sahenk Z, Yalvac ME, Amornvit J, Arnold WD, Chen L, Shontz KM, et al. Efficacy of exogenous pyruvate in Trembler(J) mouse model of Charcot-Marie-Tooth neuropathy. Brain Behav. 2018;8:e01118.","journal-title":"Brain Behav"},{"key":"518_CR58","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","volume":"164","author":"CS Constantinescu","year":"2011","unstructured":"Constantinescu CS, Farooqi N, O'Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011;164:1079\u2013106.","journal-title":"Br J Pharmacol"},{"key":"518_CR59","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/2051-5960-1-84","volume":"1","author":"DW Hampton","year":"2013","unstructured":"Hampton DW, Serio A, Pryce G, Al-Izki S, Franklin RJ, Giovannoni G, et al. Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. Acta Neuropathol Commun. 2013;1:84.","journal-title":"Acta Neuropathol Commun"},{"key":"518_CR60","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/bs.mcb.2021.12.009","volume":"168","author":"JC Nissen","year":"2022","unstructured":"Nissen JC, Tsirka SE. Preclinical model of multiple sclerosis: methods in autoimmune demyelination. Methods Cell Biol. 2022;168:67\u201386.","journal-title":"Methods Cell Biol"},{"key":"518_CR61","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jneuroim.2013.08.009","volume":"264","author":"A Musella","year":"2013","unstructured":"Musella A, Mandolesi G, Gentile A, Rossi S, Studer V, Motta C, et al. Cladribine interferes with IL-1beta synaptic effects in experimental multiple sclerosis. J Neuroimmunol. 2013;264:8\u201313.","journal-title":"J Neuroimmunol"},{"key":"518_CR62","doi-asserted-by":"publisher","first-page":"577876","DOI":"10.1016\/j.jneuroim.2022.577876","volume":"367","author":"R Ma","year":"2022","unstructured":"Ma R, Chu Y, Dou M, Jing Y, Zhao X, Li X, et al. Matrine inhibits the Wnt3a\/beta-catenin\/TCF7L2 signaling pathway in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2022;367:577876.","journal-title":"J Neuroimmunol"},{"key":"518_CR63","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jneumeth.2007.03.013","volume":"163","author":"M Peiris","year":"2007","unstructured":"Peiris M, Monteith GR, Roberts-Thomson SJ, Cabot PJ. A model of experimental autoimmune encephalomyelitis (EAE) in C57BL\/6 mice for the characterisation of intervention therapies. J Neurosci Methods. 2007;163:245\u201354.","journal-title":"J Neurosci Methods"},{"key":"518_CR64","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/cells11040660","volume":"11","author":"CP Basole","year":"2022","unstructured":"Basole CP, Nguyen RK, Lamothe K, Billis P, Fujiwara M, Vang AG, et al. Treatment of experimental autoimmune encephalomyelitis with an inhibitor of phosphodiesterase-8 (PDE8). Cells. 2022;11:660.","journal-title":"Cells"},{"key":"518_CR65","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jneuroim.2007.06.016","volume":"189","author":"S Kuerten","year":"2007","unstructured":"Kuerten S, Kostova-Bales DA, Frenzel LP, Tigno JT, Tary-Lehmann M, Angelov DN, et al. MP4- and MOG:35-55-induced EAE in C57BL\/6 mice differentially targets brain, spinal cord and cerebellum. J Neuroimmunol. 2007;189:31\u201340.","journal-title":"J Neuroimmunol"},{"key":"518_CR66","doi-asserted-by":"publisher","first-page":"862316","DOI":"10.3389\/fimmu.2022.862316","volume":"13","author":"M Ghareghani","year":"2022","unstructured":"Ghareghani M, Farhadi Z, Rivest S, Zibara K. PDK4 inhibition ameliorates melatonin therapy by modulating cerebral metabolism and remyelination in an EAE demyelinating mouse model of multiple sclerosis. Front Immunol. 2022;13:862316.","journal-title":"Front Immunol"},{"key":"518_CR67","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0165-2478(01)00339-X","volume":"81","author":"Y Okuda","year":"2002","unstructured":"Okuda Y, Okuda M, Bernard CC. Gender does not influence the susceptibility of C57BL\/6 mice to develop chronic experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein. Immunol Lett. 2002;81:25\u201329.","journal-title":"Immunol Lett"},{"key":"518_CR68","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jneuroim.2004.01.018","volume":"150","author":"TL Papenfuss","year":"2004","unstructured":"Papenfuss TL, Rogers CJ, Gienapp I, Yurrita M, McClain M, Damico N, et al. Sex differences in experimental autoimmune encephalomyelitis in multiple murine strains. J Neuroimmunol. 2004;150:59\u201369.","journal-title":"J Neuroimmunol"},{"key":"518_CR69","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nri3696","volume":"14","author":"Y Bordon","year":"2014","unstructured":"Bordon Y. Autoimmunity: a breakthrough to explain sex bias? Nat Rev Immunol. 2014;14:355.","journal-title":"Nat Rev Immunol"},{"key":"518_CR70","doi-asserted-by":"publisher","first-page":"2035117","DOI":"10.1080\/21645515.2022.2035117","volume":"18","author":"TK Goswami","year":"2022","unstructured":"Goswami TK, Singh M, Dhawan M, Mitra S, Emran TB, Rabaan AA, et al. Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders - Advances and challenges. Hum Vaccin Immunother. 2022;18:2035117.","journal-title":"Hum Vaccin Immunother"},{"key":"518_CR71","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41577-022-00718-z","volume":"22","author":"KE Attfield","year":"2022","unstructured":"Attfield KE, Jensen LT, Kaufmann M, Friese MA, Fugger L. The immunology of multiple sclerosis. Nat Rev Immunol. 2022;22:734\u201350.","journal-title":"Nat Rev Immunol"},{"key":"518_CR72","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fmicb.2011.00201","volume":"2","author":"Z Wang","year":"2011","unstructured":"Wang Z, Tapscott SJ, Chamberlain JS, Storb R. Immunity and AAV-mediated gene therapy for muscular dystrophies in large animal models and human trials. Front Microbiol. 2011;2:201.","journal-title":"Front Microbiol"},{"key":"518_CR73","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ymthe.2020.01.004","volume":"28","author":"G Gernoux","year":"2020","unstructured":"Gernoux G, Gruntman AM, Blackwood M, Zieger M, Flotte TR, Mueller C. Muscle-directed delivery of an AAV1 vector leads to capsid-specific T cell exhaustion in nonhuman primates and humans. Mol Ther. 2020;28:747\u201357.","journal-title":"Mol Ther"},{"key":"518_CR74","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322.","journal-title":"N Engl J Med"},{"key":"518_CR75","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","volume":"25","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfano LN, et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Mol Ther. 2017;25:870\u20139.","journal-title":"Mol Ther"},{"key":"518_CR76","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/mt.2014.200","volume":"23","author":"JR Mendell","year":"2015","unstructured":"Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, et al. A phase 1\/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015;23:192\u2013201.","journal-title":"Mol Ther"},{"key":"518_CR77","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell JR, Sahenk Z, Lehman K, Nease C, Lowes LP, Miller NF, et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. 2020;77:1122\u201331.","journal-title":"JAMA Neurol"},{"key":"518_CR78","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0002-9440(10)65218-2","volume":"155","author":"ME Smith","year":"1999","unstructured":"Smith ME, Eller NL, McFarland HF, Racke MK, Raine CS. Age dependence of clinical and pathological manifestations of autoimmune demyelination. Implications for multiple sclerosis. Am J Pathol. 1999;155:1147\u201361.","journal-title":"Am J Pathol"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00518-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00518-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00518-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:23:26Z","timestamp":1757143406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00518-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["518"],"URL":"https:\/\/doi.org\/10.1038\/s41434-025-00518-9","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were performed according to the guidelines approved by the Research Institute at Nationwide Children\u2019s Hospital Animal Care and Use Committee, that operates in full accordance with the Animal Welfare Act and the Health Research Extension Act (IACUC approval number: AR21-00140).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}